Rosamond Deegan Net Worth

The estimated Net Worth of Rosamond Deegan is at least $233 Tysiąc dollars as of 29 September 2014. Rosamond Deegan owns over 44 units of Trevena Inc stock worth over $232,976 and over the last 11 years Rosamond sold TRVN stock worth over $308.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rosamond Deegan TRVN stock SEC Form 4 insiders trading

Rosamond has made over 1 trades of the Trevena Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Rosamond sold 44 units of TRVN stock worth $308 on 29 September 2014.

The largest trade Rosamond's ever made was selling 44 units of Trevena Inc stock on 29 September 2014 worth over $308. On average, Rosamond trades about 15 units every 0 days since 2014. As of 29 September 2014 Rosamond still owns at least 31,105 units of Trevena Inc stock.

You can see the complete history of Rosamond Deegan stock trades at the bottom of the page.

What's Rosamond Deegan's mailing address?

Rosamond's mailing address filed with the SEC is C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA, PA, 19406.

Insiders trading at Trevena Inc

Over the last 11 years, insiders at Trevena Inc have traded over $1,042,575 worth of Trevena Inc stock and bought 4,009,638 units worth $21,947,144 . The most active insiders traders include Adam Koppel, Terrance Mcguire oraz Partners Viii, L.P.Alta Par.... On average, Trevena Inc executives and independent directors trade stock every 90 days with the average trade being worth of $969,708. The most recent stock trade was executed by Barry Shin on 28 June 2022, trading 31,785 units of TRVN stock currently worth $13,032.

What does Trevena Inc do?

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Complete history of Rosamond Deegan stock trades at Trevena Inc

Trevena Inc executives and stock owners

Trevena Inc executives and other stock owners filed with the SEC include:

• Maxine Gowen,
  Director
• Carrie Bourdow,
  President, Chief Executive Officer, Director
• Carrie L. Bourdow,
  Pres, CEO & Director
• Mark Demitrack,
  Senior Vice President and Chief Medical Officer
• Dr. Mark A. Demitrack,
  Sr. VP & Chief Medical Officer
• Robert Yoder,
  Senior Vice President and Chief Business Officer
• Dan Ferry,
  IR Contact Officer
• Scott Applebaum,
  Chief Legal and Compliance Officer and Senior Vice President of Regulatory Affairs
• Barbara Yanni,
  Independent Director
• Anne Phillips,
  Independent Director
• Jake Nunn,
  Independent Director
• Julie McHugh,
  Independent Director
• Michael Dougherty,
  Independent Director
• Scott Braunstein,
  Independent Director
• Barry Shin,
  Chief Financial Officer, Senior Vice President
• Leon Moulder,
  Independent Chairman of the Board
• Patricia M. Drake,
  Chief Commercial Officer
• Robert T. Yoder,
  Sr. VP, Chief Bus. Officer & Head of Commercial Operations
• Barry Shin,
  Sr. VP & CFO
• Michael Catalano,
  VP of Marketing
• Dr. Howard A. Rockman M.D.,
  Scientific Founder, Consultant and Member of Scientific Advisory Board
• John P. Hamill,
  VP Fin,Princ Fin&Acct Officer
• Marvin Johnson,
  Director
• Michael W. Lark,
  Sr. VP, Research & CSO
• Jason Raleigh Nunn,
  Director
• Adam Koppel,
  Director
• Yacoub Habib,
  SVP, Bus Dev & Corp Planning
• Roberto Cuca,
  Sr. VP and CFO
• David Soergel,
  Sr. VP, Clinical Development
• John M Limongelli,
  Sr. VP,General Counsel & Secy
• Jonathan Violin,
  SVP-Scientific Affairs & IR
• David Geoghegan,
  Sr. VP, Operations
• Partners Viii, L.P.Alta Par...,
  
• Francois Nader,
  Director
• Venture Management Co. V, L...,
  
• Farah Champsi,
  Director
• Robert Prachar,
  Sr. VP, Corp. Strategy
• David F Solomon,
  Director
• Rosamond Deegan,
  Sr VP, Bus Dev & Operations
• Laboratories Holdings Ltd F...,
  
• Terrance Mcguire,
  Director
• Ventures Viii, L.P.Cavanaug...,
  
• Venture Management Co. V, L...,
  
• Patricia M. Drake,
  SVP, Chief Commercial Officer
• Mark Corrigan,
  Director